Trichostatin A (TSA)

Catalog No.S1045

Trichostatin A (TSA) Chemical Structure

Molecular Weight(MW): 302.4

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

Size Price Stock Quantity  
In DMSO USD 324 In stock
USD 247 In stock
USD 447 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • Effect of TSA, SAHA and silibinin alone and in combination on left panel: IF staining for p-histone H3 Ser 10 and p-MPM-2 Ser /Thr positive cells and a-tubulin for mitotic spindle and DAPI as nuclear stain in H1299 cells. Right panel: % positive p-histone H3 Ser 10 mitotic cells and expression of p-MPM-2 Ser /Thr protein levels in H1299 cells.

    Epigenetics 2012 7(10):1161-72. Trichostatin A (TSA) purchased from Selleck.

    (B) The mRNA level of PRRT2 in the presence of different concentrations of DAC and TSA.

    Biochem Biophys Res Commun, 2017, 485(2):454-460. Trichostatin A (TSA) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

  • Western blot analysis of Acetyl-H3 and H3. 0-20μM TSA was added.

     

     

    2010 Dr. Zhang of Tianjin Medical University. Trichostatin A (TSA) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Targets
HDAC [1]
(Cell-free assay)
~1.8 nM
In vitro

Trichostatin A inhibits the proliferation of eight breast carcinoma cell lines including MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3 with mean IC50 of 124.4 nM (range, 26.4-308.1 nM), with more potency against cell lines that express ERα than the ERα-negative cell lines. Trichostatin A inhibits HDAC activity similarly in all the breast cancer cell lines with mean IC50 of 2.4 nM (range, 0.6-2.6 nM), and results in pronounced histone H4 hyperacetylation. [1] Unlike Trapoxin (TPX) and Chlamydocin which potently inhibit HDAC1 or HDAC4 but not HDAC6, Trichostatin A inhibits these HDACs to a similar extent with IC50 of 6 nM, 38 nM, and 8.6 nM, respectively. [2] Trichostatin A (100 ng/mL) treatment induces the expression of transforming growth factor β type II receptor (TβRII) in MIA PaCa-2 cells through the recruitment of p300 and PCAF into a Sp1-NF-Y HDAC complex that binds the DNA element of TβRII promoter, which is associated with a concomitant acetylation of Sp1 and an overall decrease in the amount of HDAC associated with the complex. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK 293 M{HOTWZ2dmO2aX;uJGF{e2G7 NVfRXpFwOC55zszN MUWyOIg> MXvleIhidm:u NYC1cIts\W6qYX7j[ZMhTU6jQzDhZ4V1gWyjdHnvckBidmRiaX7jdoVie2W|IFXOZWMh[WK3bnThcoNmKGmwIITo[UB1d3SjbDDj[YxtKGy7c3H0[UBidmRiYYSgeIhmKGOnbHygd5Vz\mGlZR?= NX\yc3pyOjV5OEewO|k>
TE13 NHP5V3BHfW6ldHnvckBCe3OjeR?= NUnTdIZ4OC5|zszN NHfVRXQzPGh? MlfneZAuemWpdXzheIV{KFKDU2PGOWEhdGW4ZXy= NEHZV|QzPTV5OU[2OS=>
TE13 NYTwbVJ6SXCxcITvd4l{KEG|c3H5 MVWwMlPPxE1? M4n0[|I1cA>? Mn\hbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdg>? Mnq0NlU2Pzl4NkW=
MEFs MkP2SpVv[3Srb36gRZN{[Xl? NXTEU2MzPc7:TR?= M{jKbVE3cA>? Mly5bY5kemWjc3XzJJRp\SCHUFXDJIF1fGGlaH3lcpQtKFSrcjDk[YxqfmW{eTDhcoQhfGinIHXm[olkcWWwY4mgc4YheGWmZYP0ZYwh\m:{bXH0bY9v NVTkdmFZOjV2OEK2N|Q>
SW480  M1j2eWZ2dmO2aX;uJGF{e2G7 MWWwMlHPxE1? MXS0PIg> M4XLemROW09? NIjROGhz\X[ncoPld{BGVVR? M{fWdFI2PDN2OUm3
PC3  NFvmXmtHfW6ldHnvckBCe3OjeR?= NWDkNJZbOC5zzszN MorSOFhp M2rp[GROW09? MnKzdoV3\XK|ZYOgSW1V MWWyOVQ{PDl7Nx?=
SW480  NFz4bodHfW6ldHnvckBCe3OjeR?= M1joVlAvOc7:TR?= NVHP[opWPDiq NF3rfnpFVVOR NGXIdJNifHSnboXheIV{KGmwdnHzbY9vKGGwZDDtbYdz[XSrb36= NEL2fWUzPTR|NEm5Oy=>
PC3  NGjBXHVHfW6ldHnvckBCe3OjeR?= MUCwMlHPxE1? NIOzeo81QGh? M4nC[WROW09? MlfwZZR1\W63YYTld{Bqdn[jc3nvckBidmRibXnndoF1cW:w Mn73NlU1OzR7OUe=
SW480  MWjGeY5kfGmxbjDBd5NigQ>? NEPmeZoxNjIQvF2= NYjpS25LPDiq M3PHbWROW09? MYfpcoR2[2W|IHnuZ5Jm[XOnIH;mJGhFSUNzIHHu[EBJTEGFMjDvckBUdHWpIHflcoV{KHC{b33veIVz MXGyOVQ{PDl7Nx?=
PC3  MmD2SpVv[3Srb36gRZN{[Xl? MmnYNE4y|ryP NY\JfJRkPDiq Mn;CSG1UVw>? NHHycZNqdmS3Y3XzJIlv[3KnYYPlJI9nKEiGQVOxJIFv\CCKRFHDNkBwdiCVbIXnJIdmdmW|IIDyc41wfGW{ MXeyOVQ{PDl7Nx?=
A431 M3zXeGFxd3C2b4Ppd{BCe3OjeR?= NFm3VlQzNzFyL{WwM|ExOG6P MXy0PIg> MUDEUXNQ NFXhc5pqdmirYnn0d{B1cGViY3XscEBoem:5dHi= NGXzfIYzPTN5MUC2PS=>
A431 NVrVSW5uTnWwY4Tpc44hSXO|YYm= MUK1NI5O M1fCbFIwPi9zMj:yOIg> NHe5enpFVVOR M4\sRYFkfGm4YYTld{BxOjFiYX7kJIlvcGmkaYTzJGFVTjNiZYjwdoV{e2mxbh?= NFTnfpozPTN5MUC2PS=>
MDA-MB-231 NYnQS2U6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVKwMVYxOG6P NWHaR|I6OjSq MXTEUXNQ M{HFcGlEPTBib3[gNVAxdk1? NUPkVYZbOjVzOUK3NlE>
MCF7 NX;VfIxST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDV[JExNTZyMH7N NEHQTokzPGh? MYLEUXNQ MU\JR|UxKG:oIEe1cm0> M1T3e|I2OTl{N{Kx
SKOV-3 MmS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXexMVEx|ryP NIfENHEzPGh? M2HzWGROW09? M3u4W2lEPTBib3[gOU43|ryP NXjJbGs5OjVzNkm0PVE>
A549 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILoe3kyNTFyzszN MkHNNlRp NX7qVm0xTE2VTx?= NXrJUldvUUN3MDDv[kA{NjMQvF2= NXjTVWpUOjVzNkm0PVE>
SKOV-3 NXnOWG5MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmCzNE4yNTIQvF2= MW[0PIg> MYfEUXNQ MlvsTWM2OCCxZjCwMlfPxE1? NF3id20zPTF4OUS5NS=>
A549 NYfWTmt6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUKwMlEuOc7:TR?= MnPyOFhp M4fmZmROW09? MXrJR|UxKG:oIECuNljPxE1? M3PWTlI2OTZ7NEmx
SKOV-3 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVWwMlAyNTBwOd88US=> Ml;VO|Jp NEfSNFBFVVOR MlzVTWM2OCCxZjCwMlMz|ryP Mm\vNlUyPjl2OUG=
A549 MnzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13zdFAvODFvMD65{txO NETS[4s4Omh? M{iwPGROW09? NWrONI1qUUN3MDDv[kAxNjB4zszN NFLSSnIzPTF4OUS5NS=>
HeLa M2rJWWZ2dmO2aX;uJGF{e2G7 NHniUXYzPTCwTR?= NV7Ye25bOT[q MWfEUXNQ NI\KUmxqdmO{ZXHz[ZMhS1mSMVGxJI1TVkFiZYjwdoV{e2mxbtMg M3;Qc|I2OTF4Nki4
CNE2 M{nwT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vQT|ExOC14MEDuUS=> MYiyOE81QC95Mni= MX3pcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDpckBiKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NEjRU3YzPDl4OUmwNS=>
PC3 M3TNNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXOV2VtOTByLUGwNFBvVQ>? NHXrVlAzPGh? Mo\ZTWM2OCCxZjCzNFBvVQ>? NX3yT2Y{OjR6NUS2OVg>
LNCaP MojwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrwNVAxNTFyMEDuUS=> MoPONlRp MWXJR|UxKG:oIEOwNI5O NGXieJMzPDh3NE[1PC=>
HeLa  NYjGZYpLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{j4NFLPxE1? MVG0PIg> Mlj2[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHHic5V1KDJ3JR?= MoXlNlQ5PDZzM{W=
HMEC-1  M2LzWmZ2dmO2aX;uJGF{e2G7 MnPaN|Axdk1? MmL0NlRp MX;pcoNz\WG|ZYOg[ZhxemW|c3nvckBw\sLiVlXHSnI{yqCvUl7B NX\qbGF7OjR5MUC2N|E>
HeLa MU\GeY5kfGmxbjDBd5NigQ>? MnHuNY1O NH:wVZAxNjWq NGHQeodi[m:uaYPo[ZMhfGinIITveIFtKEiGQVOgZYN1cX[rdIm= M1\SbFI1PzB5NEe0
ACP02 MnjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLYNlUxNzN3MD:1NFBvVQ>? NIjyUIIzPGh? M3zXZYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDv[kBieHC{b4jpcYF1\Wy7IEewxsAmKGG2IEK1NOKhdk1? MVKyOFY3QDV2Nx?=
ACP03 MoDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfIU5czPTBxM{WwM|UxOG6P M{DtcFI1cA>? MWLk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlib3[gZZBxem:6aX3heIVtgSB5MNMgKUBifCB{NUFCpI5O NIe3VJkzPDZ4OEW0Oy=>
U87 GBM MkfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvQcXoyODBxM{CwM|UxOCCwTR?= NELBT4Q4OiCq NVvPSpdNOTByJTDleIhidm:u NFKwNHZz\WS3Y3XzJI1m[W5iY3XscEBvfW2kZYKgZpkhOzFuIEW0MEBidmRiNUlCpEU> M4iwXlI1PDZ2OESx
U87 GBM MkXBSpVv[3Srb36gRZN{[Xl? M{f4WVExOC93MECgUo0> NXPXWJhLPDhiaB?= MUmxNFAmKGW2aHHuc4w> MW\JcoR2[2W|IGPlcoV{[2WwY3WtUIls\SCDbITldoF1cW:wczDpckBPfWOuZXHyJG1wenCqb3zv[5k> Mm[xNlQ1PjR6NEG=
RPE NU\PUXJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrtV3oxNjJxMD60M|AvQC9zIN88US=> MoPqNlQwPDhxN{KgbC=> Ml2zSG1UVw>? M1PV[YlvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJIJ6KGOnbHygZ5lkdGViYYLy[ZN1 MUCyOFQ2PjZyMh?=
HT29  NUSyOG1lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEK2dGcyQDBibl2= Mn2wO|IhcA>? MX;JR|UxKG:oIEG4NEBvVQ>? M3P5NFI1OzZ6Mk[1
hMSCs NHjT[JhHfW6ldHnvckBCe3OjeR?= M3rBVVYvOjVibl2= NW\XNnRkOjRiaB?= M37YZ2ROW09? M1rB[ZN1[WKrbHn6[ZMhUGm|dH;u[UBC[2W2eXzheIlwdiCjbnSgeIhmKEW6cILld5Nqd25ib3[gVIx2emmyb4TlcpQhT2WwZYO= NYrzS2txOjR|MUKzOVY>
Huh7  MWPGeY5kfGmxbjDBd5NigQ>? NXHtd21vOC5zL{CuOU8yNjBizszN M1;4NVI1cA>? MXvzeZBxemW|c3XzJHlVUESFMjDn[Y5mKGW6cILld5Nqd25? MnnJNlQzPjl4N{K=
SKOV3 NIjB[4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4P2SFAvODVvMjFOwG0> MnfjNVAwOjRxNEigbC=> MXvEUXNQ MorrcYVlcWG2ZYOg[5Jwf3SqIHHydoV{fCCrbjDhJINwdmOnboTyZZRqd25vIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? MmfzNlQzOjN6MEG=
A2780 NIO2e4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\PXZAxNjB3LUKg{txO NVW2fXhPOTBxMkSvOFghcA>? MmjWSG1UVw>? NULzXmx5dWWmaXH0[ZMh\3Kxd4ToJIFzemW|dDDpckBiKGOxbnPlcpRz[XSrb36tJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= NW\ye|ZqOjR{MkO4NFE>
SRA01/04  M1rie2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\vWJg5OC5{IN88US=> NYjpR4VFPDhiaB?= MoDSSG1UVw>? Mne3d5VxeHKnc4Pld{Bk\WyuIIDyc4xq\mW{YYTpc44hfGi{b4XnbEB{fXCycnXzd4lv\yC2aHWgVGk{Uy:Da4SsJJA{QE2DUFugZY5lKEWUS{GvNkB{cWewYXzpcocheGG2aIfhfZM> M1m4fVI1OTV5OEe4
HLEB3 NEDYR3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHf1OWoxNjJizszN M{n1U|Q5KGh? MXHEUXNQ NYDvdZZRe3WycILld5NmeyClZXzsJJBzd2yrZnXyZZRqd25idHjyc5VocCC|dYDwdoV{e2mwZzD0bIUhWEl|Sz;Bb5QtKHB|OF3BVGsh[W6mIFXST|EwOiC|aXfuZYxqdmdicHH0bJdigXN? Mn;lNlQyPTd6N{i=
SRA01/04  NXPyS2ZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vlW|AvPC9yLkig{txO M{nSSFQ5KGh? M3rrXWROW09? Ml;lbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? M4\0SlI1OTV5OEe4
HLEB3 NGT3dJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVSwMlQwOC56IN88US=> MUW0PEBp NE\GbmhFVVOR NH;R[5FqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NIPk[G8zPDF3N{i3PC=>
HCT116 MkX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX75emNPOC5{IN88US=> NWjDUYNrOTJiaB?= NYfTSGV1\W6qYX7j[ZMh[2WubDDhdI9xfG:|aYOgbY5lfWOnZDDifUBz[WSrYYTpc44> MlfwNlQyOjJ{M{G=
CA46 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\lN{83NzF{L{K0M|Q5KG6P M1j1[VQ5KGh? NH\qd|hqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHH0JFI1KGGwZDC0PEBvVcLi NVK1V5dOOjRyNkS5OVE>
PMNs MYDGeY5kfGmxbjDBd5NigQ>? NX\kNWs5OzBibl2= MlzUOFghcA>? M3jIWIlvcGmkaYTzJIVn\mW{b3P5eI9{cXNuIFjERWMh[WO2aY\peJkh[W6mIGLhZ{Bi[3Srdnn0fS=> MVWyN|k5QDZzNx?=
H1299 M2nrTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYOzNIhUOcLizszNxsA> MV[yOE81QC95MjDo NFf5[pdmfGijbn;s NW\SbWtScW6lcnXhd4V{KGOnbHyg[IVifGhiYX\0[ZIhOjSq MljlNlM6OTZ4MEm=
A549 NYDqb3RjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWiwMlI2NzBwNT:xJO69VQ>? NU\DPGk1OjRxNEivO|IhcA>? MV;leIhidm:u NV;wXnNKcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJIlvKGOxbnPlcpRz[XSrb36gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= M2m1[VI{QDZ5OUmx
H1299 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInSdmoxNjJ3L{CuOU8yKM7:TR?= M3\yVlI1NzR6L{eyJIg> NGqxVW1mfGijbn;s Mlf6bY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIHnuJINwdmOnboTyZZRqd25iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? M2XGU|I{QDZ5OUmx
A549 NFvrc4tCeG:ydH;zbZMhSXO|YYm= Mn\2NE42NzFizszN NGi4RYg1QCCq MWnleIhidm:u MVjpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NXTMbml5OjN6Nke5PVE>
H1299 Mlm4RZBweHSxc3nzJGF{e2G7 NUjofVRHOC53L{Gg{txO NYHJU3NCPDhiaB?= NGLLToRmfGijbn;s M4fGVIlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MVqyN|g3Pzl7MR?=
SUM149PT NWGyNmJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nKTFIwPy53L{GwJO69VQ>? MXm0PEBp MXTEUXNQ NY\yOWxocW6mdXPld{Bk\WyuIHTlZZRpKGG2IEKg{txOKGmwc3Xud4l1cX[nbIm= MWeyN|c6OjZ|OB?=
SUM190PT M4LjS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvuOVAwOTByL{K1NEBvVQ>? MUe0PEBp M4P3b2ROW09? M{jIWYlv\HWlZYOgZ4VtdCCmZXH0bEBifCB3MDDuUUB{\W6|aYTpeoVtgQ>? MnPVNlM4QTJ4M{i=
HCT1 Mn7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LtW|AvOi9zLkCvOU4xKM7:TR?= M4fxRVEzNzJ2L{O2M|Q5KGh? MoWxbY5lfWOnczDj[YxtKGSnYYToJIlvKGOxbnPlcpRz[XSrb36tJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= NX6xOYdiOjN5N{CwNFA>
Lovo NFi1e4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HGeFAvOi9zLkCvOU4xKM7:TR?= NH;hR2syOi9{ND:zOk81QCCq MYTpcoR2[2W|IHPlcIwh\GWjdHigbY4h[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= MnXoNlM4PzByMEC=
AGS NIHkV3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYD5VYdnOC5yMUWtNUDPxE1? M1TOS|czKGh? MW\pcoR2[2W|IHPlcIwh\GWjdHigZ49v[2WwdILheIlwdiCmZYDlcoRmdnSueR?= M2KxZ|I{PzR3MEK0
Huh7 M{PNbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjuNUDPxE1? NVS4VFcxOjRiaB?= Ml7uSG1UVw>? MkHwdoVlfWOnczDhZo92fCB{MDWgeoli[mmuaYT5xsA> NH7UeGYzOzZ2M{mzNy=>
ECC1 MmXWSpVv[3Srb36gRZN{[Xl? MX61NFAhdk1? MnjvOUBl NYnnSHpQTE2VTx?= MkjSbY5lfWOnczDMNWNCVcLiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1MWF7[UN? NFXqOGUzOzV|MEe2PS=>
HEC1A NFr0SmFHfW6ldHnvckBCe3OjeR?= M4fxd|UxOCCwTR?= NG\0[|I2KGR? M2ruOGROW09? MmfDbY5lfWOnczDMNWNCVcLiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1MWF7[UN? MkTHNlM2OzB5Nkm=
EN1 NU\pTJRUTnWwY4Tpc44hSXO|YYm= NYTkcVhHPTByIH7N NYm3UpI4PSCm MXvEUXNQ MnvjbY5lfWOnczDMNWNCVcLiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1MWF7[UN? NVLxeHhiOjN3M{C3Olk>
MFE296 NXfi[5VTTnWwY4Tpc44hSXO|YYm= M3n1WlUxOCCwTR?= NFqyfFE2KGR? MXrEUXNQ NHTGfJRqdmS3Y3XzJGwyS0GPwrDlfJBz\XO|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFUuSXqjQx?= MX[yN|U{ODd4OR?=
HASMCs NYm3R441TnWwY4Tpc44hSXO|YYm= M33lWVAuPTByIH7N NVjONYp{PiCm M{T0NoRwf25vcnXneYxifGW|IITo[UBmgHC{ZYPzbY9vKG:oIFjBSGMh[W6mIHPlcIwhfmmjYnnsbZR6 NWn0doIyOjN3MUi0Olc>
U373 MlH2SpVv[3Srb36gRZN{[Xl? NWPJVnZjOC5{NT:wMlUwOSEQvF2= MYmyOEBp NFPTTGxqdmO{ZXHz[ZMhWFJvQjDlfJBz\XO|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFVCgmGmQx?= NFPBXW0zOzR5NEG3NS=>
ARN8  M1u2bmZ2dmO2aX;uJGF{e2G7 NVToV3diOC5yNT2yJO69VQ>? M1vjTVI1KGh? MkWwdoVlfWOnczD0bIUhcW6mdXP0bY9vKG:oIIC1N{1l\XCnbnTlcpQh\2WwZYOgZpkhVnW2bHnuMVM> MUmyN|Q4ODV2MB?=
MCF7 NWLub2lzTnWwY4Tpc44hSXO|YYm= NInFc5QxNjB3LUKg{txO M1HTcFI1KGh? NUHUfJloemWmdXPld{B1cGViaX7keYN1cW:wIH;mJJA2Oy2mZYDlcoRmdnRiZ3Xu[ZMh[nliToX0cIlvNTN? MnfoNlM1PzB3NEC=
H1299  NHHLV3lHfW6ldHnvckBCe3OjeR?= MoO4NE4{O+LCk{JCpOK2VQ>? NFLpcoMzPC92ODDo M3n5RWROW09? M1XlR4lv[3KnYYPld{BGNWOjZHjldolvKHC{b4TlbY4hdGW4ZXzzJIRwe2ViZHXw[Y5l\W62bIm= NYHrfVFJOjN2NkG5O|U>
H1299 NFSy[VRHfW6ldHnvckBCe3OjeR?= NF;icGoxNjVizszN MkK5OFghcA>? NITMe5VFVVOR M2\ZVYlvcGmkaYTzJJRp\SCvaXfyZZRwenlicH;0[Y51cWGuIHPvcYJqdmVid3n0bEB{cWyrYnnubY4> NGT5T|MzOzR4MUm3OS=>
H1299 NHfKR3BHfW6ldHnvckBCe3OjeR?= MYewMlUh|ryP NX3BdohwPDhiaB?= MULEUXNQ MU\pcohq[mm2czD0bIUhcW64YYPpeoVv\XO|wrCgZ49u[mmwZTD3bZRpKHOrbHnibY5qdg>? NFnIcIczOzR4MUm3OS=>
MG-63  MmDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\MdWoxNjNizszN NGTXfZAyOi17NjDo MoTsSG1UVw>? NFTtT2xqdmirYnn0d{B1cGViY3XscEBoem:5dHigZ48ufHKnYYTt[Y51KHerdHigcYV1\m:{bXnu M4TKXlI{PDVzOEG3
LM8 M2HtW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFX5SFAxNjNizszN NFjuU5cyOi17NjDo M{S4V2ROW09? NXzlV|NYcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJINwNXS{ZXH0cYVvfCC5aYToJI1mfG[xcn3pci=> MVeyN|Q2OThzNx?=
K562 MYPGeY5kfGmxbjDBd5NigQ>? NFvVTmExNjVizszN NWHr[lVqOjRiaB?= MVvleIhidm:u MXrk[YNz\WG|ZYOgeIhmKGWweont[UBi[3Srdnn0fUBw\iCKRFHDd{Bkdy22cnXheI1mdnRid3n0bEBkfXKldX3pci=> NGG0TlczOzR|MEm1Oy=>
HEL MYrGeY5kfGmxbjDBd5NigQ>? NWHYWXR4OC53IN88US=> NGXBfY0zPCCq MoK4[ZRp[W6xbB?= NYDDZ2lN\GWlcnXhd4V{KHSqZTDlcpp6dWViYXP0bZZqfHlib3[gTGRCS3NiY3:teJJm[XSvZX70JJdqfGhiY4XyZ5VucW5? MUiyN|Q{ODl3Nx?=
HL60 MUPBdI9xfG:|aYOgRZN{[Xl? MUCxJO69VQ>? MXiyOEBp MYTpcoR2[2W|wrDj[YxtKGSnYYTo NF;RSIIzOzRyMEWxPS=>
KG1 NWDYO3FCSXCxcITvd4l{KEG|c3H5 M4jJelEh|ryP Ml;CNlQhcA>? MmC0bY5lfWOnc9MgZ4VtdCCmZXH0bC=> NVGwSXl2OjN2MEC1NVk>
Kazumi M1jZW2Fxd3C2b4Ppd{BCe3OjeR?= NWq1d|J5OSEQvF2= NFzNdIczPCCq M4W3S4lv\HWlZYRCpINmdGxiZHXheIg> MWWyN|QxODVzOR?=
K562 NWfvOnV6SXCxcITvd4l{KEG|c3H5 NF\aSHcyKM7:TR?= M3O2UFI1KGh? MVnpcoR2[2W|wrDj[YxtKGSnYYTo NFr1VmkzOzRyMEWxPS=>
THP1 MoTNRZBweHSxc3nzJGF{e2G7 M1nYc|Eh|ryP NHnjelAzPCCq NEHubJBqdmS3Y3XzxsBk\WyuIHTlZZRp NFrmfW8zOzRyMEWxPS=>
SH-SY5Y M{DKPGZ2dmO2aX;uJGF{e2G7 Ml7xNlUxKG6P NEnyU4YyPiCq NIXhUGtkcGGwZ3XzJIV5eHKnc4Ppc44heGG2dHXyckBw\iCpZX7ld{Bqdn[xbI\l[EBqdiClaH;s[ZN1\XKxbDDzfY51cGW|aYOsJJVxfGGtZTDhcoQh\W[obIX4 Mon6NlM{OjZ2MkK=
HEK293 MULGeY5kfGmxbjDBd5NigQ>? MVKxJOK2VcLi MoPZNVghcMLi M4PvXolvcGmkaYTzJJRp\SCtYXzpdolvNTdvbXXkbYF1\WRicnXjdpVqfG2nboSgc4Yhe3mwcHjpcIlvNTFiYXfndoVo[XSnczDpcpRwKGGpZ4Lld49u\XN? M162fVI{Ojh2OES4
HTK NYrRfIpRTnWwY4Tpc44hSXO|YYm= NGjjRpM1ODBibl2= MoXXO|IhcA>? NFHrOW9qdmirYnn0d{BVT0ZvzsNihLNKdmS3Y3XkJG16d2[rYoLvZoxie3RiRHnm[oVz\W62aXH0bY9v Mor5NlMzQDRyMEK=
HTK MmLHSpVv[3Srb36gRZN{[Xl? NEfNdFcyODBvOECwcm0> NWHTOGdYPzJiaB?= M2rqR4Jtd2OtczDUS2Yu|rMkgKPJcoR2[2WmIGLPV{BidmRiSELPNuKhSWOldX31cIF1cW:w M1PJU|I{Ojh2MECy
Caco-2  M4nHcGZ2dmO2aX;uJGF{e2G7 NHfMVGEyKML3TdMg NYCwcGREOjRiaB?= Mm\k[IVkemWjc3XzJHNGWlRicILveIVqdiCneIDy[ZN{cW:w M2rsT|I{OTl3MEew
HeLa Ml;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUK2S5V6OTByIH7N M1L5VlI1KGh? M1zTXWROW09? M3zKcGlEPTBib3[gNVAxdk1? NFqyelAzOzF4NUe0PC=>
HeLa M1TLcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjEZmw1OCCwTR?= NXTqbWdbPDhiaB?= M33kZmROW09? MXjJR|UxKG:oIESwcm0> M2HxUlI{OTZ3N{S4
HeLa NVLzRZc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfNNlAhdk1? Ml:zO|IhcA>? NF3uN5JFVVOR Mkj5TWM2OCCxZjCyNI5O NWPTdY9nOjNzNkW3OFg>
HeLa MlP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfGTGtQOTBxM{CvOVAhdk1? M1jyXlczKGh? NXT3OHhnTE2VTx?= M{[4[4lv[3KnYYPld{B1cGViboXtZoVzKG:oIF3NVEAp|pUQqH2pJIxwe3NiY3XscJMh\G:|ZTDk[ZBmdmSnboTsfS=> NULVb3hlOjNzNkW3OFg>
MDA-MB-231 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLRcGZQOjVvNECwJI5O M4nodlQ5KGh? MoHMTWM2OCCxZjCyOlMvOm6PwrC= NGrvfYEzOzB3NUG5PC=>
MCF-7  NWKzTohQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYSyOU01ODBibl2= NFWwTmY1QCCq MVfJR|UxKG:oIEKyNE41dk1? NYTPNZpUOjNyNUWxPVg>
ECC-1  NFvqfI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVGxNFAhdk1? M3XrPFI1KGh? M{njbIV1cGGwb3y= NWTDdIxncW6lcnXhd4V{KHSqZTDwdo9xd3K2aX;uJI9nKGGyb4D0c5Rq[yCwdXPs[YkhfG9iM{Wl NIDGdJMzOzB{OEiwNy=>
HEC-1A MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\JVW9COTByIH7N M2PxRVI1KGh? M2[1Z4V1cGGwb3y= MmjabY5kemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJIFxd3C2b4TpZ{BvfWOuZXmgeI8hOzln NHTjOI8zOzB{OEiwNy=>
NHAC-kn Mmi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV6xNE8yODBxNUCwJI5O NFTZeYcyOiCq MmfYSG1UVw>? Ml\GTWM2OCCxZjC1NFBvVQ>? NYTRdYtqOjNyMUe4O|E>
A549 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{GwSFI2OCCwTR?= MVS2MVczKGh? M{nmbmROW09? MX7jZZV{\XNiYTDndoVifGW{IHnubIljcXSxcomg[YZn\WO2IHPvcYJqdmVid3n0bEBVYFRib4Kg[ZJtd3Srbnni MVeyNlk6PDd6MB?=
MG-63 M{DGdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XzR|MxOCCwTR?= NIrzSYUyOiCq NGLEVIdFVVOR NXHMVo5CcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJJRwKDh4JR?= NFLGSGUzOjd7OUOzPC=>
MG-63 MmrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnCSI4{ODBibl2= MYqyOEBp MVzEUXNQ MXLpcohq[mm2czD0bIUh[2WubDDndo94fGhidH:gOlcm MlPhNlI4QTl|M{i=
MG-63 Ml30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXuzNFAhdk1? M{T2fVQ5KGh? NV:0e3NmTE2VTx?= MVzpcohq[mm2czD0bIUh[2WubDDndo94fGhidH:gOVYm MYOyNlc6QTN|OB?=
HL60  NW\1S4R4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGe3ZYkyPTBvM{WwJI5O MmC4NlQhcA>? NU[1RWJ{cW6lcnXhd4V{KGOnbHygZZBweHSxc3nzxsB4cGWwIHPvcoNmdnS{YYTpc45{KGirZ3jldkB1cGGwIEK1NEBvVQ>? NULpXHl1OjJ5NUO3N|k>
U937 MknsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NImyWWgyPTBvM{WwJI5O MXOyOEBp M1qwUolv[3KnYYPld{Bk\WyuIHHwc5B1d3Orc9Mge4hmdiClb37j[Y51emG2aX;ud{BpcWeqZYKgeIhidiB{NUCgcm0> M2Hzc|IzPzV|N{O5
SCC-6 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TiZlIxOC1|MkCwJI5O NUHCfld1OTJxMkSvOFghcA>? MX\EUXNQ MYXpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDv[kBUS0NvNjDj[YxteyCrbjDhJIRwe2VvIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? NITHWHkzOjV3MkOyNS=>
U87  NGPSfGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3f2cFExOC1|MECgcoc> NVOzNnNmOjRiaB?= NEDMW2JqdmirYnn0d{B1cGViY3XscEBoem:5dHigeI8hPzJnIDDheEAzODCwZx?= M{Lrb|IzOjdyOES5
K562 NVn0bYh4TnWwY4Tpc44hSXO|YYm= NHzSR4syKM7:TR?= MoXhNVIhcA>? NFzFfIZFVVOR MoP6[Y5p[W6lZYOgeIhmKGW6cILld5Nqd25ib3[gVnVPYDNiaX7keYNm\CCkeTC1MYF7[S2FZGK= MXGyNlE4QTF7OB?=
Reh MYTGeY5kfGmxbjDBd5NigQ>? NXLmWYhTOC5|L{Gg{txO M1HKfFEzKGh? M4\nZWROW09? M2niR4VvcGGwY3XzJJRp\SCneIDy[ZN{cW:wIH;mJHJWVlh|IHnu[JVk\WRiYomgOU1igmFvQ3TS NV\oTVlCOjJzN{mxPVg>

... Click to View More Cell Line Experimental Data

In vivo Administration of Trichostatin A at 0.5 mg/kg for 4 weeks displays potent antitumor activity in the N-methyl-N-nitrosourea carcinogen-induced rat mammary carcinoma model, without any measurable toxicity at doses up to 5 mg/kg. [1] Single intraperitoneal doses of 10 mg/kg Trichostatin A in nontransgenic and spinal muscular atrophy (SMA) model mice results in increased levels of acetylated H3 and H4 histones and modest increases in survival motor neuron (SMN) gene expression. Administration of Trichostatin A at 10 mg/kg/day improves survival, attenuates weight loss, and enhances motor behavior in the SMA model mice. [5]

Protocol

Kinase Assay:

[1]

+ Expand

In vitro HDAC activity:

Total cellular extracts are prepared from each breast cancer cell line (MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, or SK-BR-3). A 20 μL crude cell extract (~2.5 ×105 cells), in the presence of varying concentrations of Trichostatin A in 0.1% (v/v) ethanol or 0.1% (v/v) ethanol as vehicle control, are incubated for 60 minutes at 25 °C with 1 μL (~1.5 × 106 cpm) of [3H]acetyl-labeled histone H4 peptide substrate (NH2-terminal residues 2-20) that has been acetylated with [3H]acetic acid, sodium salt (3.7 GBq/mmol) by an in vitro incorporation method. Each 200 μL reaction is quenched with 50 μL of 1 M HCl/0.16 M acetic acid and extracted with 600 μL of ethyl acetate, and released [3H]acetate is quantified by scintillation counting. IC50 values are determined graphically using nonlinear regression to fit inhibition data to the appropriate dose-response curve.
Cell Research:

[1]

+ Expand
  • Cell lines: MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3
  • Concentrations: Dissolved in absolute ethanol, final concentrations ~10 μM
  • Incubation Time: 96 hours
  • Method:

    Cells are exposed to various concentrations of Trichostatin A for 96 hours. After treatment, cell proliferation is estimated using the sulforhodamine B colorimetric assay. Cell viability is determined by trypan blue exclusion.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Inbred virgin female (Ludwig/Wistar/Olac) rats bearing tumors induced with NMU
  • Formulation: Dissolved in DMSO
  • Dosages: ~5 mg/kg/day
  • Administration: Injection s.c.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 23 mg/mL (76.05 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 302.4
Formula

C17H22N2O3

CAS No. 58880-19-6
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02959905 Recruiting Metastatic Melanoma BGI, China|Sun Yat-sen University December 2016 Phase 1
NCT02486965 Recruiting Fibromyalgia University Hospital, Brest October 2015 --
NCT01954433 Recruiting Glenohumeral Arthritis and/or Rotator Cuff Tear Arthropathy (TSA)|Rotator Cuff Tear (RCR)|Trapeziometacarpal Osteoarthritis (TMC OA) Matthias Flury|Winterthur Institute of Health Economics (WIG), Switzerland|Schulthess Klinik November 2013 --
NCT01575106 Unknown status Pain Massachusetts General Hospital June 2012 --
NCT02762903 Completed Osteoarthritis Columbia University August 2009 --
NCT00914173 Completed Pain Medasense Biometrics Ltd November 2008 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to obtain the enantiomers of TSA, as separate chemicals: R-TSA and S-TSA. Do you have any ideas?

  • Answer:

    Our S1045 Trichostatin A (TSA) is R enantiomer.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Trichostatin A (TSA) | Trichostatin A (TSA) supplier | purchase Trichostatin A (TSA) | Trichostatin A (TSA) cost | Trichostatin A (TSA) manufacturer | order Trichostatin A (TSA) | Trichostatin A (TSA) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID